Drugs / AMG 509
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04221542 | Mar 2020 → Mar 2030 expected | prostate cancer | Amgen | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04221542 ↗ |
| Route | Intravenous | “AMG 509 administered as an IV infusion” NCT04221542 ↗ |